Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.
These three loci implicated skeletal and spinal cord development-linked pathways in chronic back pain.
After a series of duplication and rearrangement events, the genes involved in two key pathways producing morphine, codeine, and noscapine have clustered in the genome.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The team said that by understanding why some members of this family don't feel pain, they could unearth new drug targets to treat others with chronic pain.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.
The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.